(Insulin glargine + insulin lispro) LA is under clinical development by Adocia and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Insulin glargine + insulin lispro) LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Insulin glargine + insulin lispro) LA overview

BioChaperone combo, is a pre-mixed liquid formulation containing both long-acting insulin analog glargine and fast-acting insulin analog lispro is under development for the treatment of type 1 diabetes and type 2 diabetes. The drug candidate is administered subcutaneously. The drug candidate acts by targeting insulin receptor (IR). The drug candidate is developed based on BioChaperone technology.

Adocia overview

Adocia is a biotechnology company, which carries out the development of therapeutic proteins and peptides. The company’s clinical pipeline product offerings include Biochaperone Lispro insulin, Biochaperone Combo for type-2 diabetes, M1Pram for type-1 diabetes, Biochaperone Glucagon for hyperglycemia, Biochaperone GLA GLP-1 basal insulin and Biochaperone Glucagon GLP-1 for Obesity. Its BioChaperone is a proprietary technology platform developed from polymers, oligomers and small organic compounds, protects proteins from enzymatic degradation and enhances performance. The company also provides preclinical stage cell therapy concentrating on the development of a hydrogel scaffold for people diagnosed with type 1 diabetes. Adocia is headquartered in Lyon, Auvergne-Rhone-Alpes, France.

For a complete picture of (Insulin glargine + insulin lispro) LA’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.